Health

Novel Complement-Targeting Agent Shows Benefit in Myasthenia Gravis

TribeNews
By TribeNews 1 View Add a Comment
0 Min Read
Novel Complement-Targeting Agent Shows Benefit in Myasthenia Gravis

MedPage Today) — SAN FRANCISCO — The investigational complement-targeting agent claseprubart was safe and led to significant improvements in generalized myasthenia gravis (MG), the phase II MaGic trial showed.
The trial tested two doses of…

Leave a Comment
Ads Blocker Image Powered by Code Help Pro

Ads Blocker Detected & This Is Prohibited!!!

We have detected that you are using extensions to block ads and you are also not using our official app. Your Account Have been Flagged and reported, pending de-activation & All your earning will be wiped out. Please turn off the software to continue

You cannot copy content of this app